Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 2/20 | 0.36 |
| ▸ | GRM3 | Q14832 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.33 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2194685 | 0.75 | THRB (0.35) | GRM2GRM3KMT2AALDH1A1MAPK1 | |
| SCHEMBL4990698 | 0.70 | THRB (0.38) | KMT2AALDH1A1MAPK1EPHX2MEN1 | |
| SCHEMBL1994420 | 0.69 | THRB (0.33) | KMT2ASMN1; SMN2ALDH1A1EPHX2MEN1 | |
| SCHEMBL6865794 | 0.69 | THRB (0.40) | GRM2GRM3ALDH1A1EPHX2HSD11B1 | |
| SCHEMBL1990174 | 0.68 | THRB (0.32) | KMT2ASMN1; SMN2ALDH1A1 | |
| SCHEMBL6740182 | 0.67 | KMT2A (0.33) | KMT2ASMN1; SMN2ALDH1A1EPHX2MEN1 | |
| SCHEMBL6346239 | 0.67 | KMT2A (0.33) | KMT2ASMN1; SMN2ALDH1A1EPHX2MEN1 | |
| SCHEMBL26939593 | 0.67 | KMT2A (0.33) | GRM2GRM3KMT2ASMN1; SMN2ALDH1A1 | |
| SCHEMBL9724273 | 0.67 | THRB (0.39) | GRM2GRM3ALDH1A1EPHX2 | |
| SCHEMBL2190387 | 0.67 | THRB (0.35) | GRM2GRM3KMT2AALDH1A1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9522868-B2 | Tetrakis(ether-substituted formylphenyl) | HONSHU CHEMICAL INDUSTRY CO., LTD. (JP) | 2016-12-20 | — | — | US | disclosed |
| US-20160016884-A1 | NEW TETRAKIS(ETHER-SUBSTITUTED FORMYLPHENYL) | HONSHU CHEMICAL INDUSTRY CO., LTD. (JP) | 2016-01-21 | — | — | US | disclosed |
| US-20110172457-A1 | TETRAKIS(ETHER-SUBSTITUTED FORMYLPHENYL) AND NEW POLYNUCLEAR POLYPHENOL DERIVED FROM THE SAME | HONSHU CHEMICAL INDUSTRY CO., LTD. (JP) | 2011-07-14 | — | — | US | disclosed |
| US-20090068586-A1 | SILSESQUIOXANE RESIN, POSITIVE RESIST COMPOSITION, RESIST LAMINATE, AND METHOD OF FORMING RESIST PATTERN | TOKYO OHKA KOGYO CO., LTD. (JP) | 2009-03-12 | — | — | US | disclosed |
| US-20060222866-A1 | Silsesquioxane resin, positive resist composition,layered product including resist and method of forming resist pattern | TOKYO OHKA KOGYO CO., LTD. (JP) | 2006-10-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160016884-A1 | NEW TETRAKIS(ETHER-SUBSTITUTED FORMYLPHENYL) | AHR, PAH, ALK | GRM2 2100/4885GRM3 858/4885KMT2A 1370/4885 |
| US-20110172457-A1 | TETRAKIS(ETHER-SUBSTITUTED FORMYLPHENYL) AND NEW POLYNUCLEAR POLYPHENOL DERIVED FROM THE SAME | AHR, PAH, ARNT | GRM2 2238/4885GRM3 1029/4885KMT2A 1921/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.